Literature DB >> 9326754

Plasma levels of arginine vasopressin elevated in patients with major depression.

L van Londen1, J G Goekoop, G M van Kempen, A C Frankhuijzen-Sierevogel, V M Wiegant, E A van der Velde, D De Wied.   

Abstract

Mentally healthy subjects show increased plasma concentrations of the neuropeptides, arginine vasopressin (AVP) and oxytocin (OT), under conditions of stress, but data are lacking about plasma concentrations of AVP and OT in patients with major depression. We thus assessed plasma concentrations of AVP and OT in patients with major depression (n = 52) and healthy controls (n = 37). Mean plasma AVP concentrations were higher in the group of depressed patients than in controls. A subgroup of 16 patients showed very high levels of plasma AVP, but no other feature differentiating this subgroup from the other patients was found. In-patients showed higher plasma AVP levels than out-patients, and melancholic patients had higher plasma AVP levels than did nonmelancholic patients. Plasma AVP levels were slightly related to psychomotor retardation and significantly inversely to neuroticism. Patients' plasma OT concentrations had a wider range than in controls. AVP and AVP-mediated functions may be a factor in the clinical picture of depression, possibly by influencing the activity of the hypothalamic-pituitary-adrenal axis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326754     DOI: 10.1016/S0893-133X(97)00054-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  58 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.

Authors:  M Iijima; T Yoshimizu; T Shimazaki; K Tokugawa; K Fukumoto; S Kurosu; T Kuwada; Y Sekiguchi; S Chaki
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 3.  The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings.

Authors:  David M Cochran; Daniel Fallon; Michael Hill; Jean A Frazier
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

Review 4.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

Review 5.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 6.  Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin.

Authors:  Timothy G Dinan; Lucinda V Scott
Journal:  J Anat       Date:  2005-09       Impact factor: 2.610

7.  Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.

Authors:  Karine Fabio; Christophe Guillon; Carl J Lacey; Shi-fang Lu; Ned D Heindel; Craig F Ferris; Michael Placzek; Graham Jones; Michael J Brownstein; Neal G Simon
Journal:  Bioorg Med Chem       Date:  2011-12-20       Impact factor: 3.641

Review 8.  Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease.

Authors:  J M Goldstein; R J Handa; S A Tobet
Journal:  Front Neuroendocrinol       Date:  2013-12-16       Impact factor: 8.606

9.  Posttraumatic stress disorder and partner-specific social cognition: a pilot study of sex differences in the impact of arginine vasopressin.

Authors:  Amy D Marshall
Journal:  Biol Psychol       Date:  2013-03-05       Impact factor: 3.251

Review 10.  Oxytocin and postpartum depression: delivering on what's known and what's not.

Authors:  Sohye Kim; Timothy A Soeken; Sara J Cromer; Sheila R Martinez; Leah R Hardy; Lane Strathearn
Journal:  Brain Res       Date:  2013-11-14       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.